2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|January 2, 2004
- Pharmaceutical Technology-01-02-2004
- Volume 28
- Issue 1
Coprocessed Excipients for Solid Dosage Forms
Author(s)Arvind K. Bansal
The authors examine the development and performance of coprocessed excipients, including testing them for flowability, compressibility, amd dilution potential.
Advertisement
Articles in this issue
over 22 years ago
Manufacturing Execution Systemsover 22 years ago
State-of-the-Art Packaging Machinesover 22 years ago
January 2004over 22 years ago
Medicare Bill Contains Significant Changes for Drug Manufacturersover 22 years ago
The Bioterrorism Actover 22 years ago
New Supply-Chain Dynamicsover 22 years ago
In the Spotlight--February 2004over 22 years ago
January 2004Advertisement
Related to this article
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains that developing a molecule requires a holistic view of its chemical, physical, and biological properties.
Advertisement
Advertisement